

# Hypoxia-inducible C-to-U coding RNA editing downregulates *SDHB* in monocytes

**BACKGROUND:** RNA editing is a post-transcriptional regulatory mechanism that can alter the coding sequences of certain genes in response to physiological demands. Most RNA editing occurs in the form of A-to-I conversion, whereas C-to-U RNA editing, especially within the coding sequences, is rare in mammals. We previously identified C-to-U RNA editing (C136U, R46X) which inactivates a small fraction of succinate dehydrogenase (SDH; mitochondrial complex II) subunit B gene (*SDHB*) mRNAs in normal steady-state peripheral blood mononuclear cells (PBMCs). SDH is a heterotetrameric tumor suppressor complex which when mutated causes paraganglioma tumors that are characterized by constitutive activation of hypoxia inducible pathways. Here, we studied regulation, extent and cell type origin of *SDHB* RNA editing. **METHODS:** We used short-term cultured PBMCs obtained from random healthy donors, performed monocyte enrichment by cold aggregation, and employed a novel allele-specific quantitative PCR method, flow cytometry, immunologic cell separation, gene expression microarray, database analysis and high-throughput RNA sequencing. **RESULTS:** While the editing rate is low in uncultured monocyte-enriched PBMCs (average 2.0%, range 0.4%-6.3%, n=42), it is markedly upregulated upon 2-day exposure to hypoxia (average 18.2%, range 2.8%-49.4%, n=14) and during macrophage differentiation in normoxia peaking on culture days 5 and 6 (average 10.1%, range 2.7%-18.8%, n=17). Further purified CD14-positive monocytes showed increased percentages of C136U transcripts by 1.25-fold in normoxic cultures and 1.68-fold in hypoxic cultures (n=4). CD14-negative lymphocytes showed no evidence of *SDHB* editing. The *SDHB* genomic DNA remained wild-type during increased RNA editing. Microarray analysis showed expression changes in genes of wound healing and immune response pathways as the editing rate increased in normoxic cultures. High-throughput sequencing of *SDHB* and *SDHD* transcripts confirmed the induction of C136U RNA editing but showed no additional verifiable coding edits. Bioinformatic analysis of *SDHB* RNA sequence data from 16 normal human tissues from the Illumina Body Map and from 45 samples representing 23 different cell types from the ENCODE projects confirmed the occurrence of site-specific C136U editing in whole blood (1.7%) and two primary

CD14+ monocyte samples (1.9% and 2.6%). In contrast, the other cell types showed an average of 0.2% and 0.1% C136U editing rates in the two databases, respectively. CONCLUSIONS: These findings demonstrate that C-to-U coding RNA editing of certain genes is dynamically induced by physiologically relevant environmental factors and suggest that epigenetic downregulation of *SDHB* by site-specific RNA editing plays a role in hypoxia adaptation of monocytes.

1 **Bora E. Baysal<sup>1,†</sup>, Kitty De Jong<sup>1</sup>, Biao Liu<sup>2</sup>, Jianmin Wang<sup>2</sup>, Santosh K. Patnaik<sup>3</sup>, Paul K.**  
2 **Wallace<sup>1</sup>, R. Thomas Taggart<sup>1</sup>**

3 Departments of Pathology and Laboratory Medicine<sup>1</sup> Biostatistics and Bioinformatics<sup>2</sup> and Thoracic  
4 Surgery<sup>3</sup>, Roswell Park Cancer Institute, Buffalo, NY 14263, USA

5

6 *†To whom correspondence should be addressed:*

7 Bora E. Baysal, MD, PhD

8 Department of Pathology, Roswell Park Cancer Institute

9 Elm & Carlton Streets, Buffalo, NY 14263, USA

10 Tel: 716-845-3204; Email:bora.baysal@roswellpark.org

11

12

13

14

15

## 16 INTRODUCTION

17 RNA editing is a post-transcriptional regulatory mechanism which often results in conversion of  
18 adenosine to inosine (A-to-I) (Nishikura 2010). Recent whole transcriptome sequence analyses  
19 reveal abundant A-to-I type RNA editing in non-coding and Alu-containing transcript regions while  
20 RNA editing of protein encoding regions, especially of non-A-to-I types, appears to be very rare  
21 (Kleinman, Adoue & Majewski 2012; Piskol, et al., 2013). Site-specific C-to-U RNA editing  
22 leading to amino acid recoding of an endogenous gene in normal mammalian cells was previously  
23 confirmed, to our knowledge, only in the *APOB* gene encoding apolipoprotein B (Blanc & Davidson  
24 2003). C-to-U editing of *APOB* is catalyzed by APOBEC1 cytidine deaminase that generates a  
25 shorter protein isoform in intestinal epithelial cells. APOBEC1 also inactivates 4%-17% of  
26 neurofibromatosis type 1 (*NF1*) gene transcripts by site-specific C-to-U RNA editing in certain  
27 high-grade NF1 tumors but not in normal cells (Skuse, et al., 1996).

28 We previously identified *SDHB* C-to-U mRNA editing (C136U) at low steady-state levels in  
29 peripheral blood mononuclear cells (PBMCs) of normal individuals using reverse transcription (RT)  
30 and semi-quantitative PCR (Baysal 2007). Analysis of the purified PBMC subsets in a single donor  
31 showed that the C136U editing rate was higher in monocytes than in lymphocytes. SDH is a central  
32 metabolic enzyme in Krebs cycle (Rutter, Winge & Schiffman 2010) and a tumor suppressor for  
33 hereditary paraganglioma (PGL) (Baysal, et al., 2000). SDH catalyzes the oxidation of succinate to  
34 fumarate during aerobic respiration. In anaerobically respiring mitochondria of lower organisms,  
35 SDH is inactive and fumarate is often reduced to succinate in a reverse reaction catalyzed by  
36 fumarate reductase (Muller, et al., 2012). Germline inactivating mutations in the nuclear-encoded  
37 SDH subunit genes, primarily in *SDHB* and *SDHD*, cause PGL tumors (Burnichon, et al., 2012)  
38 which show constitutive activation of the hypoxia-inducible pathways. PGL tumors recapitulate the

39 high-altitude associated carotid body (CB) paragangliomas (Saldana, Salem & Travezan 1973),  
40 increase in severity with increased altitudes (Astrom, et al., 2003; Cerecer-Gil, et al., 2010) and share  
41 transcriptome characteristics with Von-Hippel Lindau (VHL) disease tumors (Dahia, et al., 2005).  
42 The VHL gene product plays an important role in normoxic degradation of hypoxia-inducible factors  
43 (HIFs) (Kaelin & Ratcliffe 2008). Succinate and reactive oxygen species that accumulate upon SDH  
44 inactivation were implicated as downstream messengers leading to stabilization of HIF1 $\alpha$  in  
45 normoxic conditions (Selak, et al., 2005; Guzy, et al., 2008) although mechanisms of PGL  
46 tumorigenesis remains unconfirmed.

47 The *SDHB* C136U RNA editing converts a highly conserved arginine residue to a premature stop  
48 codon (R46X) shortly after the mitochondrial targeting signal and inactivates the *SDHB* gene  
49 product, the iron-sulfur subunit of the SDH complex. The R46X germ line mutation was previously  
50 described in multiple index patients with PGL confirming its pathogenicity (Bayley, Devilee &  
51 Taschner 2005). Here, we studied the *SDHB* C136U transcript editing in short-term cultured PBMCs  
52 using a novel allele specific quantitative PCR assay (AS qPCR), high-throughput genetic methods,  
53 immunophenotyping, immunoseparation, morphology and database analysis. Our aim was to  
54 determine the prevalence, distribution, cell type origin and other factors influencing *SDHB* editing  
55 using a reproducible assay to gain functional insights. We found that *SDHB* C136U editing is present  
56 at low levels in fresh uncultured total and monocyte-enriched PBMCs, but it markedly increases  
57 during macrophage differentiation *in vitro* and upon short-term hypoxic exposure in monocytes.  
58 These results provide unprecedented evidence that functional transcript dosage for a central  
59 metabolic enzyme is regulated by environmentally-inducible site-specific C-to-U RNA editing.

## 60 MATERIALS AND METHODS

### 61 *PBMC isolation and cell culture*

62 Leukocytes were isolated from Trima leukoreduction filters (Terumo BCT, Lakewood, CO) of  
63 anonymous healthy platelet donors following an IRB review and determination as non-human  
64 subject research. PBMCs were purified by histopaque 1077 (Sigma-Aldrich, St. Louis, MO) and  
65 washed twice with RPMI-1640/10% fetal bovine serum (FBS) to remove residual platelets. Each  
66 filter often gave  $5 \times 10^8$  or more PBMCs. Monocytes were enriched by the cold aggregation method  
67 (Mentzer, et al., 1986) with certain modifications. PBMCs were suspended in 35 ml RPMI-1640 in a  
68 50 ml polypropylene tube and incubated at 4 °C for 1 h on a rocker panel for homotypic aggregation  
69 of monocytes. For monocyte enrichment, the tube was positioned upright, underlaid with 6 ml FBS  
70 and incubated overnight at 4 °C. The cell precipitate under the serum was collected for culture.  
71 Monocyte enrichment was approximately 70% (n=5) by short-term precipitation (up to 3 hours) and  
72 27% (n=10) by overnight precipitation over serum as determined by percentages of the CD14+ cells  
73 by flow cytometry. The non-aggregating upper layer was markedly depleted of monocytes (less than  
74 4%, n=3). We used the overnight precipitation method which gave higher yield of total cells and  
75 were associated with higher levels of C136U editing in culture. Precipitated cells under the serum  
76 were centrifuged for 10 min at 250xg and suspended in 20 ml RPMI-1640 with 10% FBS and  
77 penicillin/streptomycin. Cell density was calculated by a hemocytometer (improved Neubauer ,  
78 InCyto, Covington, GA). After further dilution, two milliliters of the cell suspension was distributed  
79 to each well of a six-well tissue culture plate (Costar, Corning Incorporated, Corning, NY). Editing  
80 rates were determined in daily collected individual wells. We cultured  $21\text{-}30 \times 10^6$  cells/2 ml per well  
81 (also see results). Cultures were incubated at, 5% CO<sub>2</sub> with either 21% O<sub>2</sub> (normoxia) or 1% O<sub>2</sub>  
82 combined with 94% nitrogen (hypoxia). Hypoxic cultures were pre-incubated at 37 °C, 21% O<sub>2</sub> for

83 approximately 3 hours before being placed in the hypoxia chamber (XVIVO system, BioSpherix,  
84 Lacona, NY). Fresh culture media was added after 7 days in culture.

85 The THP-1 monocytic leukemia cell line was purchased from ATCC (Manassas, VA). Various  
86 cytokines/differentiating agents were added for the following final concentrations: macrophage  
87 colony stimulating factor (M-CSF; 50 ng/ml), granulocyte-macrophage (GM)-CSF (50 ng/ml),  
88 interleukin 4 (IL4; 50 ng/ml, vitamin D (10 nM), retinoic acid (1  $\mu$ M), PMA  
89 (4-beta-phorbol-12-myristate-13-acetate; 100 nM). Cytokines were purchased from Peprotech  
90 (Rocky Hill, NJ) and differentiating agents were purchased from Sigma-Aldrich.

#### 91 *Microscopy and imaging*

92 Standard tissue culture monitoring and imaging was performed using an Axio microscope (Zeiss,  
93 Jena, Germany). Adherent aggregates (approximately 100 micron or larger in diameter) were  
94 counted at low power (2.5X) magnification. Live image photographs were taken using a Leica  
95 AF6000LX system (Houston, TX) which is comprised of a Leica DMI-6000B microscope and Leica  
96 LAS AF software interface.

#### 97 *Nucleic acid isolation and analysis*

98 RNA and DNA were isolated using Trizol (Life Technologies, Grand Island, NY) and DNA Wizard  
99 genomic DNA purification kit (Promega, Madison, WI), respectively. Nucleic acid lysis buffer or  
100 Trizol was added directly to the adherent cells in plate well. Nucleic acid was quantified by a  
101 spectrophotometer (Nanodrop, Thermo Scientific, Wilmington, DE). Oligonucleotide primers and  
102 templates were obtained from IDT Technologies (Coralville, IA).

103 RT and qPCR were performed following the manufacturer's kits and instructions (LightCycler 480II,  
104 Roche, Indianapolis, IN). Complementary DNA from total RNA (1-2  $\mu$ g) was synthesized using a  
105 mixture of random hexanucleotide and oligo-dT<sub>12</sub> primer mixture. qPCR amplification of cDNAs  
106 was performed and crossing point (Cp) levels of C136U (T assay) and total *SDHB* (total assay) were  
107 determined separately. Each assay was performed in duplicate or triplicate wells. T assay and total  
108 assay had the same forward oligonucleotide primer for *SDHB* exon 1 and different oligonucleotide  
109 reverse primers in exon 2, where the C136U editing occurs. The reverse primer for the T assay had  
110 an extra T at its 3'-end relative to the reverse primer in the common assay. (Oligonucleotide primers  
111 and probes used in this study are listed in supplemental Table S1.)

112 The relative amount of the edited transcripts was calculated by the delta-Cp method by  
113 exponentiating the total transcript Cp minus the edited transcript Cp value to the power of 2. This  
114 approach assumes 100% duplication efficiency per cycle in both assays. Control PCR reactions were  
115 performed to test the specificity and amplification efficiency of oligonucleotide primer pairs using  
116 synthetic oligonucleotide templates. Assays with 8-fold serially diluted synthetic oligonucleotide  
117 templates for the wild-type and C136T edited sequences showed a duplication efficiency of 107%  
118 for both total and T assays between 1 femtomole and 0.245 attomole (Supplemental Table S2). The  
119 mutation-specific primer had a high specificity for the edited transcripts, with an average false  
120 positive amplification rate of 1.38% when the control wild type oligonucleotide template sequence  
121 was amplified in an over 25,000-fold concentration range. When 100% T template was used, the  
122 average estimate of the C136U edited transcripts was 91% between 8 femtomoles and 0.245  
123 attomoles. These control experiments suggest that AS qPCR estimates may be slightly lower than the  
124 true editing rates. We chose this stringent AS qPCR method to ensure we did not overestimate the  
125 C136U editing rates. The estimated percentage of edited transcripts using this method was highly

126 reproducible in biological samples. For example, a set of 14 samples containing both low and high  
127 levels of edited transcripts gave very similar results in two replicate experiments with a Pearson  
128 correlation coefficient of 99.4%. In each assay, a positive control sample which had a mutation rate  
129 of 15%-17% was included. Relative quantification of cytidine deaminase (*CDA*) and *SDHB* mRNA  
130 expression was performed by  $2^{-(\Delta\Delta Ct)}$  method (Livak & Schmittgen 2001) using  
131 expression levels of the housekeeping *B2M* beta-2 microglobulin transcripts for normalization.

### 132 *Microarray analysis of gene expression*

133 Expression profiling was accomplished using the Human HT-12 whole-genome gene expression  
134 array and direct hybridization assay (Illumina, San Diego, CA). Initially, 500 ng total RNA was  
135 converted to cDNA, followed by in vitro transcription to generate biotin-labeled cRNA using the  
136 Ambion Illumina TotalPrep RNA Amplification Kit (Ambion, Austin, TX) as per manufacturer's  
137 instructions. 750 ng of the labeled probes were then mixed with hybridization reagents and  
138 hybridized overnight at 58 °C to the HT-12v4 BeadChips. Following washing and staining with  
139 Cy3-streptavidin conjugate, the BeadChips were imaged using the Illumina iScan Reader to measure  
140 fluorescence intensity at each probe. The intensity of the signal corresponds to the quantity of the  
141 respective mRNA in the original sample.

142 The background corrected gene expression levels were extracted from BeadChip using Illumina's  
143 Genome Studio (v2011.1) gene expression module (v1.9.0). The  $\log_2$ -transformed expression levels  
144 were quantile normalized using lumi Bioconductor package in R (Du, Kibbe & Lin 2008) For data  
145 quality control, we excluded the genes with detection P value greater than 0.05 (i.e.,  
146 indistinguishable from the background noise). 18941 out of 34686 genes passed this filtering for  
147 downstream analysis.

148 The limma Bioconductor package (Smyth 2004) was used to calculate the level of differential gene  
149 expression. Briefly, a linear model was fit to the data (paired design, with cell means corresponding  
150 to the different condition and a random effect for array) and selected contrasts of condition (i.e., case  
151 vs. control) were performed. A list of differentially expressed genes with  $P < 0.05$  and  $\geq 2$  fold-change  
152 was obtained and analyzed for enriched Gene Ontology (GO) categories and KEGG pathways using  
153 NCBI DAVID Bioinformatics Resources (Huang da, Sherman & Lempicki 2009) . The enriched GO  
154 terms and KEGG pathways with  $P < 0.05$  and  $\geq 5$  genes were kept.

#### 155 *Accession number*

156 Microarray data have been deposited in the NCBI Gene Expression Omnibus  
157 ([www.ncbi.nlm.nih.gov/geo/](http://www.ncbi.nlm.nih.gov/geo/)) under accession number GSE45900.

#### 158 *High-throughput RT-PCR amplicon sequencing*

159 *SDHB* and *SDHD* gene transcripts were amplified by RT-PCR with oligonucleotide primers targeting  
160 5'- and 3'-untranslated regions (primer sequences can be obtained from authors) using Transcriptor  
161 reverse transcriptase (Roche) and Ultra2 *Pfu* high fidelity DNA polymerase (Agilent, Santa Clara,  
162 CA) . Libraries were prepared using the Nextera XT DNA sample preparation kit (Illumina) for  
163 high-throughput sequencing was on a MiSeq personal sequencing platform (Illumina).

#### 164 *Flow cytometry*

165 Cells ( $0.5-1 \times 10^6$ ) were pelleted by centrifugation at 400g for 5 minutes and incubated for 20 minutes  
166 at room temperature in a total volume of 100  $\mu$ l with a titrated cocktail of allophycocyanin  
167 (APC)-conjugated mouse anti-CD14 antibody (Invitrogen, Carlsbad, CA), Brilliant-violet 421  
168 conjugated CD16 (BioLegend, San Diego, CA), phycoerythrin (PE)-conjugated mouse anti-CD163  
169 antibody (Trillium Diagnostics, Brewer, ME), fluorescein isothiocyanate (FITC)-conjugated mouse

170 anti-CD206 (BD Biosciences, San Jose, CA), and PE-Cy7-conjugated mouse anti-HLA-DR antibody  
171 (BD Biosciences), followed by a wash in phosphate buffered saline (PBS; pH 7.4) and resuspension  
172 in 500  $\mu$ l PBS. Viability is assessed by Live/Dead Yellow (Invitrogen). Flow cytometric acquisition  
173 was performed on a FACS Aria I flow cytometer (BD Biosciences) equipped with four laser  
174 excitation sources (405 nm at 30 mW; 488 nm at 15 mW; 561 nm at 30 mW, and 631 nm at 17 mW)  
175 that was quality-controlled on a daily basis by using BD cytometer setup and tracking beads and  
176 FACS DiVa software (BD Biosciences). The filter configurations for the PMTs measuring  
177 fluorescence emission of the applied fluorochromes were 450/50 nm (Brilliant-violet 421); 530/30  
178 nm (FITC); 582/15 nm (PE); 780/60 nm (PE-Cy7); and 660/20 nm (APC). Autofluorescence and  
179 single-color controls were acquired to perform spectral overlap compensation using the automated  
180 compensation matrix feature in FACS DiVa software. A forward scatter threshold was applied to  
181 eliminate electronic noise and small particles from the flow cytometric acquisition. A total of 20,000  
182 scatter-inclusive events were acquired for each specimen. Data analysis was performed with FlowJo  
183 software version 10.0.4 (Tree Star, Ashland, OR).

#### 184 *Isolation of CD14<sup>+</sup> monocytes*

185 Monocytes were isolated either by flow cytometric gating of CD14<sup>+</sup> cells (both dim and strong  
186 intensity) on a BD FACS Aria I flow sorter, or by CD14 microbeads (Miltenyi Biotec Inc. Auburn,  
187 CA) following manufacturer's protocol. Flow cytometry showed 93% or higher purity after CD14  
188 purification.

#### 189 *Immunocytochemical staining*

190 PBMCs were grown in tissue culture chamber slides (Labtek, Scotts Valley, CA). Before staining,  
191 medium was aspirated and adherent cells were washed once with PBS. Adherent cells were fixed by

192 alcohol-based cytology fixative (Leica) and air dried. For antigen retrieval, slides were heated in the  
193 steamer for 20 minutes in a citrate buffer (pH 6.0), followed by a 20 minute cool down. Endogenous  
194 peroxidase was quenched with aqueous 3% H<sub>2</sub>O<sub>2</sub> for 10 minutes and washed with PBS with 0.05%  
195 Tween 20 (Sigma). Slides were loaded on an autostainer (Dako, Carpinteria, CA) and a serum-free  
196 protein blocker (catalog #X0909, Dako) was applied for 5 minutes, blown off, and the antibody  
197 applied for one-hour. Biotinylated goat anti-mouse IgG (Jackson Immuno Research Labs, catalog  
198 #115-065-062) was applied for 30 minutes, followed by the Vectastain Elite ABC Kit (Vector Labs,  
199 Burlingame, CA) for 30 minutes, and the 3, 3'-diaminobenzidine chromagen (Dako) for 5 minutes.  
200 Finally, the slides were counterstained with hematoxylin, dehydrated, cleared and cover slipped.

#### 201 *Western blot analysis*

202 Cell lysates were prepared using 75 µl of M-PER protein extraction reagent (Thermo, Waltham, MA)  
203 per approximately 20X10<sup>6</sup> washed cells. The concentration of proteins in lysates was determined  
204 with the colorimetric Pierce 660 nm protein assay (Thermo). For electrophoresis, lysates (40–60 µg  
205 of protein) were boiled for 5 min in buffer containing 50 mM Tris, 2% SDS and 143 mM  
206 β-mercaptoethanol. After electrophoresis in Mini-PROTEAN™ TGX pre-cast 4%–15% gradient  
207 polyacrylamide gels (Bio-Rad, Hercules, CA) at 15–30 mA for 90 min, proteins were transferred  
208 overnight at 30 mA in 10% methanol-containing Tris-glycine buffer to 0.45 µ polyvinylidene  
209 difluoride membrane (GE Healthcare, Little Chalfont, UK). For immunoblotting, membranes were  
210 blocked in Tris-buffered saline (TBS; 10 mM Tris-HCl and 150 mM NaCl at pH 7.4) with 0.05%  
211 Tween-20 and 5% non-fat milk (Carnation™, Nestle, Vevey, Switzerland), and then incubated in the  
212 same solution with a primary mouse monoclonal anti-SDHB antibody (ab14714, Abcam,  
213 Cambridge, MA) at room temperature for an hour. After washing in TBS/Tween-20 for 30 minutes,  
214 membranes were incubated in TBS/Tween-20/milk with a horseradish peroxidase-conjugated

215 secondary antibody for 1 hour at room temperature. Membranes were then washed in TBS/Tween-20  
216 for 30 min, incubated in Luminata Forte™ chemiluminescence reagent (Thermo), and exposed to  
217 photographic film (Thermo). Mouse anti-beta-actin (clone C4, Santa Cruz Biotechnology, Dallas,  
218 TX) and horseradish peroxidase-conjugated goat anti-mouse IgG (Invitrogen) antibodies were used  
219 at 1:200 and 1:2500 dilutions, respectively. Densitometry of Western blot signals was performed  
220 using the gel analysis method of ImageJ (version 1.47) after scanning the photographic films in  
221 grayscale at 400 dpi on an Epson Perfection v700 scanner (Schneider,Rasband & Eliceiri 2012).  
222 SDHB signals were normalized to those of beta-actin.

### 223 *RNA sequence database analysis*

224 BAM sequence alignment files of RNA-seq reads mapped against the GRCh37/hg19 human genome  
225 assembly were downloaded from public data repositories of the Illumina® BodyMap 2.03 and  
226 ENCODE human transcriptome projects (Derrien, et al., 2012,Tilgner, et al., 2012). The two projects  
227 have analyzed poly-A+ RNA using the Illumina® HiSeq 2000 or Genome Analyzer II or Iix RNA  
228 sequencing platforms. From the BodyMap project, data for all 16 tissues from different healthy  
229 individuals was obtained. From the ENCODE project, data for 23 different cell-types/cell-lines (22  
230 with biological duplicates) was obtained.

231 For each BAM file, the mpileup routine in samtools7 0.1.19 (March 2013 release) was used with its  
232 default setting, (Li, et al., 2009) which weighs alignment quality and ignores duplicate reads, to  
233 identify RNA-seq reads that align against chromosome 1 regions for the 843 b-long coding region of  
234 human *SDHB* mRNA (NCBI RefSeq8 no. NM\_003000.2). The output of mpileup was then scanned  
235 with a Python 2.7 script to quantify the number of RNA-seq reads with one of five base calls (A, C,  
236 G, T or ambiguous) at each nucleotide position. The fraction of RNA-seq reads with a base call of T

237 for c.136C was compared against the fraction with a base call of T at any of the 213 C  
238 nucleotide-bearing positions of the *SDHB* coding region. Statistical significance of any difference  
239 was determined with two-tailed Chi-square test with Yates correction using Prism 6.0c software  
240 (GraphPad, La Jolla, CA).

241 None of the 67 single nucleotide polymorphisms (SNPs) that have been documented for the *SDHB*  
242 coding region in dbSNP10 database (04-25-2012 release, NCBI dbSNP build 138 phase I) is at the  
243 genomic position of *SDHB* c.136C.

#### 244 *Statistical analysis*

245 Unless specified otherwise, statistical analyses of experimental data was performed using the online  
246 interface of SISA at <http://www.quantitativeskills.com/sisae> (Uitenbroek, 2013) using two-tailed  
247 non-parametric tests, graphics and descriptive statistics were generated in Excel (version 10;  
248 Microsoft, Redmond, WA). Means and standard errors are depicted by horizontal bars in the figures.

## 249 RESULTS AND DISCUSSION

### 250 Analysis of C136U mutation rate in PBMCs by RT and AS qPCR

251 To determine the prevalence, distribution, cell type origin and other factors influencing *SDHB*  
252 editing, we developed a highly specific and reproducible assay for allele specific quantitative PCR  
253 amplification (AS qPCR) of the total and edited C136U *SDHB* mRNAs (see methods). Using this  
254 assay, we found that the C136U transcripts were very low or absent in B cell lymphoblastoid and  
255 fibroblastic cell lines. The editing occurred at slightly higher levels in PBMCs isolated from fresh  
256 blood than in the cell lines (Figure 1A). To study the relative contribution of monocytes and  
257 lymphocytes to *SDHB* editing, we performed monocyte enrichment using the well-established cold  
258 aggregation method (Mentzer, et al., 1986) with certain modifications (see methods). This method  
259 essentially separates PBMCs into cold-aggregating monocyte-enriched and non-aggregating  
260 monocyte-depleted (i.e., predominantly lymphocytic) compartments. Monocyte-enriched samples by  
261 the cold aggregation method showed higher editing rates than the matched PBMCs (2.16% versus  
262 1.48%, n=36,  $P=1.6 \times 10^{-5}$ , Wilcoxon matched pairs signed ranks test) and than the matched  
263 monocyte-depleted samples (1.47% versus 0.58%, n=10,  $P=0.005$ , Wilcoxon matched pairs signed  
264 ranks test) (Figure 1A). To further confirm monocyte-origin of the edited transcripts, we isolated  
265 peripheral blood monocytes to >92% purity by CD14+ microbeads and tested the mutation rates in  
266 three samples. In each sample, a higher mutation rate was found in the monocytes than the CD14-  
267 lymphocytes (average 0.84% vs 0.38%). A positive but weak correlation was found between the  
268 CD14+ monocyte-fraction and the C136U editing rate in cold-aggregated PBMC samples (Figure  
269 1B). These results indicate that C136U editing occurs in freshly isolated monocytes in low but  
270 statistically significantly higher rates than in lymphocytes.

271

272 **C136U editing rate increases during short-term culture of PBMCs in a time-dependent**273 **manner**

274 We cultured monocyte-enriched PBMCs for *in vitro* macrophage differentiation by plate adherence  
275 in the presence of 10% fetal bovine serum (FBS) at standard culture conditions as described  
276 (Roiniotis, et al., 2009). Flow cytometry showed that the fraction of CD14<sup>+</sup> cells among the  
277 adherent cells on culture days 5-6 (25.9% ± 5.2%; n=4) was comparable to the uncultured  
278 monocyte-enriched PBMC samples (27.2%± 2.7%; n=10). Initial cultures showed that the fraction of  
279 the edited transcripts increased in the adherent cells on days 5-7 then decreased to baseline levels on  
280 later days (Supplemental Figure S1A). Short-term cultures showed that the editing rates were lower  
281 in the first three days than on days 5-7 (3.54% versus 11.62%, n=15, P=8X10<sup>-4</sup>, Wilcoxon matched  
282 pairs signed ranks test, Figure 1C). The uncultured monocyte-enriched PBMC samples had lower  
283 C136U editing rates than their matched cultures on days 5 and 6 in 17 of the 17 samples (1.7% ±  
284 0.2% versus 10.06% ± 0.8%; P=2.9X10<sup>-4</sup>, Wilcoxon matched pairs signed ranks test). To confirm  
285 monocyte origin of the edited transcripts in the cultured samples, we performed flow cytometric  
286 sorting of the attached CD14<sup>+</sup> cells from culture days 5-8 which essentially separated  
287 monocyte/macrophages from lymphocytes to >95% purity. In five of five samples, the CD14<sup>+</sup> cells  
288 showed higher editing rates than the CD14<sup>-</sup> cells (Figure 1D). The editing rate was higher among the  
289 adherent cells than those in the supernatant (Figure 1E). Collectively, these findings indicate that  
290 C136U editing is induced in monocyte/macrophage lineage cells during culture of  
291 monocyte-enriched PBMCs in a time-dependent manner.

292 The maximum mutation rate reached on days 4-8 varied markedly among samples from 1.2% to  
293 18.8%. Total number of cultured cells per well correlated positively but very weakly with the  
294 maximum mutation rate (Supplemental Figure S1B). The maximum C136U editing rate trended  
295 higher when the total number of monocyte-enriched PBMCs was over 21 million per well versus 20  
296 million or less per well, though this difference did not reach statistical significance ( $10.9\% \pm 1.23\%$ ;  
297  $n=16$  versus  $8.54\% \pm 1.03\%$ ;  $n=15$ ;  $P=0.1$ ; Mann Whitney U test, one-tailed).

### 298 **Morphologic evaluation of cultures associated with C136U editing**

299 We noted the development of three dimensional adherent aggregates (AAs) in monocyte-enriched  
300 PBMC cultures, especially in those that had the highest C136U editing rates. These aggregates were  
301 detectable within 12 hours and increased in density and size up to a week in culture (Figure 2A and  
302 2B). Hourly photographic imaging in the first two days showed that the aggregates start as a loose  
303 collection of cells and become larger and more compact by merging and recruitment of individual  
304 cells (Supplemental video S1). Cultures with low AA densities showed lower mutation rates than  
305 those with intermediate or high AA densities ( $n=16$ ,  $P=0.015$ , Mann-Whitney U test; Figure 2C).

306 Morphologic examination showed that the AAs were primarily comprised of intermediate-size cells  
307 that generally had round non-convoluted nuclei and a moderate amount of cytoplasm. Occasional  
308 lymphocytes and large monocytoïd cells with curved nuclei were also noted within the aggregates.  
309 In contrast, numerous individually attached macrophages, including those with spindle-like  
310 morphology or multi-nucleation, had more abundant cytoplasm compared to cells in the AAs (Figure  
311 2D). Immunostaining with an anti-CD163 antibody confirmed that most cells in the AAs were  
312 aggregated monocytes/macrophages (Figure 2E). These results suggest that C136U editing primarily  
313 occurs in aggregating monocytes that are in the process of differentiating to macrophages.

314

315 **Microarray analysis of differentially expressed genes associated with increased C136U editing**  
316 **in normoxia**

317 We performed pairwise microarray gene expression analysis of four sets of low-editing (day 3) and  
318 high-editing (day 5-8) samples cultured in normoxia (Table 1) to evaluate (a) global changes in  
319 cellular pathways; (b) whether adherent aggregates are associated with micro-environmental  
320 hypoxia; and (c) changes in the SDH subunit and cytidine deaminase family of genes. Analysis  
321 showed that 171 genes were upregulated and 123 genes were downregulated genes by at least  
322 two-fold at a statistically significant level ( $P < 0.05$ ). The subset of these genes ( $n=55$ ) that showed  $\geq$   
323 fold-change is shown in Supplemental Table S3. The complete list is available on GEO database  
324 under accession number GSE45900. No SDH subunit or APOBEC family gene met these criteria.  
325 Cytidine deaminase (*CDA*) was the only gene from the cytidine deaminase family of genes that had  
326 its expression level changed significantly, with a 3.1-fold increase. qPCR analysis confirmed  
327 upregulation of *CDA* expression (average 3.7-fold) and little change in *SDHB* expression (average  
328 0.98-fold) in the high-editing samples relative to the low-editing ones. Significant gene expression  
329 changes coordinately occurred in functionally related genes in several Gene Ontology (GO)  
330 categories ( $n=159$ ). This number decreased to 10 after Bonferroni correction for multiple testing was  
331 applied (Supplemental Table S4). These 10 categories included defense to wounding, inflammatory,  
332 immune and defense responses, taxis, chemotaxis, carboxylic and organic acid transport, locomotory  
333 behavior and regulation of cell proliferation. Notably, hypoxia-response genes were not categorically  
334 different between the low and the high editing samples. These results indicate that significant gene  
335 expression changes occur in inflammatory and immune response pathways during increase in *SDHB*  
336 editing and that *CDA* is a candidate gene for enzymatic C136U deamination.

337

**338 Flow cytometric characterization of cultures associated with C136U editing**

339 To evaluate monocyte macrophage maturation in PBMC culture, we performed flow cytometric  
340 characterization of the attached cells using monocyte/macrophage-associated antibodies for CD14,  
341 CD16, CD163, HLA-DR and CD206, a mannose receptor associated with M2 type macrophage  
342 polarization that promotes wound healing (Porcheray, et al., 2005).

343 Cold-aggregated uncultured PBMCs showed a discrete and relatively uniform monocytic population  
344 that is positive for CD14, HLA-DR and CD163; but negative for CD206 and largely negative for  
345 CD16 (Figure 3). Cultured adherent cells at day 6, which showed an increased editing rate, contained  
346 a CD14+ population comprised of larger cells with more complexity and were dim-positive for  
347 CD206, heterogeneously positive for CD14 and brightly positive for HLA-DR. CD16 and CD163  
348 patterns were similar and showed a heterogeneous negative-to-positive range. Analysis of the  
349 adherent cells at day 15, when the editing rates are typically low and the AAs are loose  
350 (Supplemental Figure S1C), showed a mature macrophage population that had increased complexity  
351 and a more uniform antigenic profile, including homogenous positivity for CD14, CD16, CD163,  
352 HLA-DR and CD206. Taken together, these results demonstrate that high C136U editing peaks  
353 during monocyte macrophage differentiation in normoxic culture.

**354 C136U editing in cytokine-treated PBMC cells and in monocytic leukemia cell line THP-1**

355 When monocyte-enriched PBMC cultures were treated with M-CSF and GM-CSF/IL4 to facilitate  
356 macrophage and dendritic cell differentiation, respectively, lower editing rates were seen compared  
357 to the control cultures that contained only 10% FBS (P=0.012, n=8, and P=0.04, n=5, respectively,  
358 Wilcoxon matched pairs signed ranks test Supplemental Figure S1D). We also tested C136U editing

359 rates in the monocytic leukemia cell line THP-1. We added macrophage differentiation agents to the  
360 media with 10% FBS including phorbol ester PMA, retinoic acid and vitamin D. Significant C136U  
361 editing was not identified (less than 1%) either in the untreated THP-1 cell line or after treatment  
362 with the differentiating agents. Similarly, hypoxia exposure of the THP-1 cell line showed no  
363 increase in C136U levels on days 1, 2 and 3 (less than 1%). These results indicate that C136U  
364 editing primarily occurs in mature monocytes during differentiation to macrophages in the presence  
365 of serum under normoxic culture conditions and that cytokine-driven macrophage or dendritic cell  
366 differentiation or leukemic transformation reduces editing rates.

### 367 **Induction of C136U editing by hypoxia**

368 Because tissues with inflammation and infarction harboring monocyte/macrophage lineage cells are  
369 often hypoxic and because monocyte-macrophage differentiation occurs in tissues where oxygen  
370 pressure is lower than that in blood (Roiniotis, et al., 2009), we evaluated the role of hypoxia on  
371 C136U editing. We observed that monocyte-enriched PBMC cultures in hypoxia did not develop the  
372 firmly adherent aggregates associated with high editing rates in the normoxic cultures and that  
373 essentially all cells were in suspension. The fraction of viable CD14<sup>+</sup> monocytes in the hypoxic  
374 supernatants on culture day 2 was similar to the original uncultured samples as evaluated by flow  
375 cytometry (20.9% versus 20.4%, n=4). The editing rate in the hypoxic cultures increased in the first  
376 three days with a peak on day 2, when it is typically low in the normoxic control cultures (Figure 1C  
377 and 4A). In five of the 14 samples, C136U editing rates were higher (21%-49%) than in any  
378 normoxic culture. Hypoxia increased the fraction of C136U transcripts by 0.4% to 46% on culture  
379 day 2. Pairwise comparison of the editing rates in supernatant cells in hypoxia versus total cells in  
380 normoxia from 14 different samples in the first three days showed marked upregulation of C136U  
381 editing by hypoxia ( $P=2 \times 10^{-7}$ , n=42, Wilcoxon matched pairs test; Fig. 4B). Hypoxia increased

382 C136U fractions in 39 of 42 pairwise comparisons from 14 samples cultured in normoxia and  
383 hypoxia for three days. Comparison of the flow sorted CD14<sup>+</sup> and CD14<sup>-</sup> cell populations  
384 confirmed that monocytes were the main source of C136U editing in hypoxia (Figure 4E). RT-qPCR  
385 analysis showed marked upregulation of *CDA* (average 7.5-fold change on day 2, n=6) and  
386 downregulation of *SDHB* (average 0.37-fold change on day 3, n=6) in the hypoxic cultures relative  
387 to the control gene beta 2 microglobulin. Western blot analysis of a monocyte-enriched PBMC  
388 sample cultured in normoxic and hypoxic conditions showed no marked changes in the expression  
389 *SDHB* protein product (Figure 4D), suggesting that the impact of C136U editing on protein  
390 expression levels is subtle and quantitative. The variable increase in the percentage of C136U  
391 transcripts by hypoxia could be caused by unknown technical or biological factors including variable  
392 fraction of monocytes in donors, variation in inherent enzymatic activity of the putative editing  
393 enzyme or nonsense mediated decay pathway activation.(Chang, Imam & Wilkinson 2007).

#### 394 **Analysis of genomic DNA for C136T editing**

395 To test whether the C136U RNA mutation has a corresponding C-to-T genomic DNA mutation in  
396 *SDHB* exon 2, we compared mutant RNA and DNA levels using our previously described  
397 semi-quantitative method based on PCR amplification and *Taq1* restriction enzyme digestion (Baysal  
398 2007). We found no evidence of a corresponding DNA mutation in the hypoxic samples containing  
399 high levels of C136U RNA mutations (Figure 4C). These results indicate that C136U mRNA editing  
400 occurs during or after transcription.

#### 401 **High throughput sequencing of *SDHB* and *SDHD* transcripts**

402 To obtain a global view of transcript editing in the *SDHB* and the *SDHD* genes, we performed high  
403 throughput sequencing of the full length coding transcripts obtained by RT and high-fidelity PCR.

404 We sequenced the four pairs of normoxic cultures that were characterized by microarray gene  
405 expression analyses. Each pair derived from the same PBMC and contained a sample with a low  
406 C136U editing rate (day 3 culture) and a sample with a high C136U editing rate (day 5-8 culture).  
407 Interrogation of the transcript sequences confirmed C136U mutations in each of the high-editing-rate  
408 sample. On average, 40% higher editing levels were seen by high throughput sequencing than those  
409 estimated by AS qPCR (Table 1). No additional canonical RNA edits in the form of A-to-I/G or  
410 C-to-U/T changes were identified in the *SDHB* transcripts. No additional *SDHB* transcript variants  
411 could be identified by Sanger sequencing. In contrast, Sanger sequencing confirmed C136U in all  
412 four samples that showed high editing rates by AS qPCR and by high-throughput sequencing  
413 (Supplemental Figure S1E). Similarly, *SDHD* transcripts showed no evidence of RNA editing by  
414 high-throughput sequencing. Taken together, these results demonstrate that *SDHB* C136U editing is  
415 not accompanied by other transcript variants either in *SDHB* or *SDHD* and suggest that a  
416 site-specific C-to-U RNA editing mechanism regulates the *SDHB* functional transcript dosage.

#### 417 **Analysis of transcriptome sequence databases**

418 We examined RNA sequencing data of the Illumina Human Body Map and ENCODE Human  
419 Transcriptome projects (Derrien, et al., 2012; Tilgner, et al., 2012; Brazma, et al., 2003) for sequence  
420 variations in the ORF region *SDHB* mRNA. As expected, among the 16 normal human tissues from  
421 Human Body Map, the highest levels of *SDHB* C136U editing was seen in white blood cells (1.7%),  
422 with the other 15 tissues showing an average editing level of 0.2% (SD=0.3%), with ovary (1%) and  
423 kidney (0.9%) being those with the highest levels among the 15 (Supplemental Table S5). Among  
424 the 45 samples of 23 different cell-types of the ENCODE set, the editing rate was highest for the two  
425 primary CD14+ monocytes (1.9% and 2.6%), with the other samples showing an average 0.1%  
426 (SD=0.2%) editing rate (Supplemental Table S6). The editing rates noted for the samples for white

427 blood cells and the monocytes are unlikely to be a result of sequencing error since a base call of U  
428 instead of C was made in only 0.04%-0.09% of the reads when all 213 C-bearing positions of the  
429 *SDHB* coding region were examined ( $P < 0.001$ , Chi square test). These results support our earlier  
430 conclusions that C136U editing occurs at low but statistically significant levels in peripheral blood  
431 monocytes.

## 432 CONCLUSIONS

433 We found that an acquired RNA nonsense mutation (R46X) introduced by C-to-U RNA editing  
434 dynamically reduces the *SDHB* functional transcript dosage in monocytes during early macrophage  
435 differentiation and upon short-term exposure to hypoxia. The fraction of C136U transcripts was  
436 variable in monocyte-enriched PBMC cultures and peaked around 19% in normoxic cultures but  
437 increased to up to 49% within 2 days in hypoxia. The editing rates must be higher in pure monocytes  
438 because CD14<sup>+</sup> cell isolation increased the percentages of C136U transcripts by 1.25-fold in  
439 normoxic cultures and 1.68-fold in hypoxic cultures. Gene expression analyses identified *CDA* as a  
440 candidate gene for *SDHB* editing. To our knowledge, these results provide the first examples of  
441 hypoxia-inducible coding RNA editing and a programmed mutation targeting an endogenous nuclear  
442 gene in myeloid cells.

443 On the basis of genetic studies on SDH-mutated paragangliomas that show constitutive activation of  
444 hypoxia-inducible pathways, we hypothesize that reduction in the *SDHB* dosage by RNA editing  
445 facilitates hypoxia adaptation in monocytes by amplifying hypoxia signaling from mitochondria. We  
446 speculate that the programmed *SDHB* RNA editing during normoxic macrophage differentiation  
447 might serve to augment signaling of inflammatory hypoxia. Although the precise mechanisms  
448 linking hypoxia sensing and signaling to *SDHB* RNA editing remain to be determined, parallels can

449 be drawn between the monocytes circulating in the high-oxygen environment of the peripheral blood  
450 and subsequently migrating into the hypoxic areas where differentiation into macrophages occurs  
451 versus certain facultatively aerobic organisms such as the intestinal parasitic worm *Ascaris suum* (*A.*  
452 *suum*). *A. suum* spores living in open air are exposed to high oxygen concentrations and utilize  
453 SDH; whereas parasitic adult worms living in the hypoxic environment of intestine use fumarate  
454 reductase (Kita, et al., 2002). Thus, suppression of SDH might be an evolutionarily conserved  
455 metabolic adaptation to hypoxia achieved by diverse molecular mechanisms and might contribute to  
456 increased monocyte/macrophage survival observed under hypoxia due to enhanced glycolysis  
457 (Roiniotis, et al., 2009).

458 More broadly, our results extend previous observations associating external factors with differential  
459 A-to-I RNA editing (Garrett & Rosenthal 2012; Balik, et al., 2013; Sanjana, et al., 2012) and  
460 demonstrate in a robust experimental model that C-to-U coding RNA editing of certain genes occurs  
461 dynamically in a cell type and environment-dependent manner. Our findings suggest that gene  
462 targets of RNA editing could be missed by whole transcriptome sequence analyses unless tissues are  
463 examined in their physiologically relevant different states. If the threshold for significant RNA  
464 editing is set at 10% or more in whole transcriptome sequence analyses (for example in Park, et al.,  
465 2012), the *SDHB* gene would be identified as a target of RNA editing in monocytes only upon  
466 exposure to hypoxia or during macrophage differentiation but not in peripheral blood.

467 If *SDHB* editing aberrantly occurs in the paraganglionic tissues, an increased risk of paraganglioma  
468 development might ensue. Recent evidence suggests that tumor suppressor gene functions can be  
469 compromised by as little as a 20% decrease in gene dosage (Berger, Knudson & Pandolfi 2011).  
470 Dosage sensitivity of the SDH complex is specifically supported by the imprinted transmission of  
471 PGL tumors by *SDHD* mutations as paternal but not maternal transmission of *SDHD* mutations is

472 known to cause highly penetrant tumors. Recent discovery of tissue-specific imprint marks in the  
473 vicinity of *SDHD* suggests that subtle allelic expression differences can result in discordant  
474 penetrances depending on which allele carries the mutation (Baysal, et al., 2011). If programmed  
475 downregulation of *SDHB* by RNA editing improves monocyte survival in hypoxic environments,  
476 therapeutic manipulation of this pathway might provide a tool to modify risk in common diseases  
477 associated with macrophage infiltration.

478 **FIGURE LEGENDS**

479 **Figure 1** *SDHB* C136U RNA editing is induced in monocytes during short-term culture. **(A)** C136U  
480 editing is measured in 9 lymphoblastoid cell lines and one fibroblastic cell line, freshly isolated  
481 PBMCs (n=50), PBMCs monocyte-enriched by cold-aggregation (Mono+; n=42) and  
482 monocyte-depleted PBMCs comprised of largely lymphocytes (Mono-; n=10). Horizontal lines  
483 represent mean  $\pm$  standard errors throughout the figures. **(B)** Fraction of the C136U transcripts  
484 weakly correlates with the CD14+ monocyte percentage in monocyte-enriched PBMCs (Pearson  
485 correlation coefficient  $r=0.36$ ). **(C)** Impact of short-term culture on C136U editing. Short-term  
486 culture of five monocyte-enriched PBMCs shows upregulation of C136U editing in adherent cells in  
487 culture days 5-7 compared to days 1-3. Day 0 represents the uncultured samples. **(D)** Flow  
488 cytometric sorting of CD14+ versus CD14- adherent cells on culture days 5-8 shows higher mutation  
489 rates in monocyte-macrophage lineage than in lymphocytes ( $P=0.04$ ,  $n=5$ , Wilcoxon matched pairs  
490 signed ranks test). **(E)** C136U editing is lower among non-adherent cells in the supernatant than in  
491 adherent cells (4.3% versus 9.8%) on culture days 5-7 ( $n=19$  wells from 11 samples on days 5-7,  
492  $P=2.1 \times 10^{-4}$ , Wilcoxon matched pairs signed ranks test).

493

494 **Figure 2** *SDHB* C136U RNA editing rate correlates with adherent monocyte-rich adherent  
495 aggregates (AA) in normoxic culture. The AAs on culture days 1 **(A)** and 5 **(B)** are shown (5X low  
496 power field; vertical bars equal to 1 mm). The culture is initiated with 30 million cells per well. The  
497 AAs grow in size until approximately days 5-7 when the C136U editing rate also usually peaks. **(C)**  
498 High editing rates are seen in cultures with intermediate and high density of adherent aggregates.  
499 Aggregate densities are grouped as follows: Low= less than 10 aggregates/per 5X low power field  
500 (lpf); Intermediate=10-20 aggregates/lpf; High= more than 20 aggregates/lpf **(D)** Giemsa stain

501 highlights an adherent aggregate on day 6 culture. Individually attached mature macrophages have  
502 mostly round eccentric nuclei and abundant cytoplasm. Occasional multi-nucleated macrophages  
503 (arrowheads) and rare small lymphocytes (green arrows) are also present. Macrophages within the  
504 aggregate are smaller with less cytoplasm and occasionally have curved nuclei (arrows). **(E)** CD163  
505 immunostaining of adherent aggregates. Immunocytochemical staining for  
506 monocyte-macrophage-specific antigen CD163, a scavenger receptor for hemoglobin-haptoglobin  
507 complex, demonstrates that the adherent aggregates are primarily comprised of  
508 monocyte/macrophage lineage cells. Individually attached macrophages outside the aggregate also  
509 stain with variable intensity (short arrows); while numerous small lymphocytes are negative (long  
510 arrows).

511

512 **Figure 3** *SDHB* C136U RNA editing increases during monocyte-macrophage maturation. Flow  
513 cytometric evaluation of monocyte-macrophage maturation is shown in uncultured cold aggregated  
514 PBMCs (first column), adherent cells on culture day 6 (second column) and adherent cells on culture  
515 day 15 (third column). The day 15 culture shows a relatively homogenous large (indicated by high  
516 forward scatter, FSC-A) macrophage population that has high complexity (indicated by high side  
517 scatter, SSC-A) and is positive for CD206 (mannose receptor), HLA-DR and CD163. In contrast,  
518 uncultured monocytes are largely a uniform population that is smaller with less complexity and is  
519 negative for CD206. The day 6 culture, which has 11.6% C136U editing rate, shows a CD14+  
520 population that is brightly positive for HLA-DR, dim-positive for CD206 and negative for CD163.  
521 CD14+ monocyte-macrophage and lymphocyte populations are marked by green and red,  
522 respectively.

523 **Figure 4** Hypoxia induces *SDHB* C136U RNA editing. **(A)** The editing rates are higher on days  
524 1-3 in hypoxia and on days 5, 6 in normoxia. The average of four independent cultures is  
525 presented. **(B)** C136U editing rates in 12 independent cultures in hypoxia versus normoxia  
526 during 3 days of culture are shown. The editing rates were obtained from supernatant in all  
527 hypoxic cultures (first column) and from total cell population in normoxic cultures, except in two  
528 normoxic cultures where only supernatant was collected (second column). D0 samples represent  
529 the original uncultured cold aggregated PBMCs. **(C)** PCR amplification and *Taq1* restriction  
530 enzyme (RE) digestion shows no evidence of C136T DNA mutation in *SDHB* exon 2 genomic  
531 DNA (gDNA) (right panel) in the same samples with high C136U RNA editing rates (left panel).  
532 The C13U RNA editing rates above the lanes were measured by AS qPCR. RT- and  
533 gDNA-PCRs generate amplicon sizes of 285 bp and 233 bp, respectively. *Taq1* RE digestion of  
534 wild type cDNA and gDNA sequences generates 159 bp/126 bp and 131 bp/102 bp bands,  
535 respectively. C136U/T mutation destroys the RE site. **(D)** Western blot analysis of normoxic  
536 (N) and hypoxic (H) cultures from one donor shows no major changes in *SDHB* protein  
537 expression, normalized against beta actin, as the editing rate increases in hypoxia, but possibly a  
538 subtle decrease when the C136U percentage is 16.1% on day 2 in hypoxia. Hypoxic cultures  
539 were sampled twice a day, 10 h apart. **(E)** The editing rates are shown for flow sorted CD14+  
540 and CD14- viable cells from day 2 hypoxic cultures (n=4). In all experiments, hypoxic and  
541 control normoxic culture derive from the same donor (i.e., oxygen tension is the only variable).

542 **AUTHORSHIP**

543 BEB conceptualized the study and wrote the manuscript. BEB, RT, JW and PKW designed  
544 experiments. RT, KDJ and BEB performed experiments. BL and JW performed the bioinformatic  
545 analysis of microarray expression data. SP performed the ENCODE and Illumina database  
546 analysis. All authors approved the final manuscript.

547 **ACKNOWLEDGMENTS**

548 We thank anonymous platelet donors, personnel at RPCI's core facilities for assistance with flow  
549 cytometry, high-throughput sequencing, immunocytochemistry and hypoxia treatment, Eric Kannisto  
550 for technical help, and the Department of Pathology and Laboratory Medicine for administrative and  
551 financial support.

552

553 **CONFLICT OF INTEREST DISCLOSURE**

554 The authors declare no conflict of interest.

555 **Supplemental material**

556 **Supplemental Figure legends**

557 **Supplemental Figure S1 (A)** Impact of long-term culture and cell density on C136U editing are  
558 shown. Five monocyte-enriched PBMCs were cultured long-term and the C136U editing rates were  
559 measured. The editing rate was higher in adherent cells on days 5-7 than in the uncultured  
560 monocyte-enriched PBMCs and on days 12-14 and 19-21 ( $P=0.017$ ,  $n=5$ , one-way ANOVA).

561 **(B)** Maximum C136U editing rate in the adherent cells shows very weakly positive correlation with  
562 the total number of monocyte-enriched PBMCs per well. Total number of samples=31.

563 **(C)** Attached aggregates (AAs) on culture day 20 are shown. The AAs start loosening after one  
564 week in culture and eventually appear as flat areas of increased cellular density. This culture was fed  
565 with fresh RPMI-1640/10% FBS on day 8.

566 **(D)** Cytokine mediated differentiation towards macrophages or dendritic cells reduce C136U editing  
567 rates. Cultures containing 10% FCS showed higher mutation rates than those treated with M-CSF  
568 ( $p=0.012$ ) or GM-CSF/IL4 ( $p=0.04$ ). Multi-day averages from two PBMC cultures are shown.  
569 Matched samples were collected on days 4-8 for the m-CSF culture ( $n=8$ ) and days 4-6 for the  
570 GM-CSF/IL4 cultures ( $n=5$ ). The editing rate was obtained from adherent cells in 10% FCS and  
571 m-CSF treated (macrophage-differentiation) wells and from non-adherent cells in supernatant in  
572 GM-CSF/IL4-treated (dendritic cell-differentiation) wells.

573 **(E)** Sanger sequencing confirms C136U RNA editing in all four samples that showed high editing  
574 rates by RT-qPCR and high-throughput sequencing. Chromatograms show examples of a sample  
575 with a low editing rate (sample 1, day3 in Table 1) and one with a high editing rate (sample 4, day 7  
576 in Table 1). C136U variant is shown by arrows.

577

578 **Supplemental Video S1** Culture is initiated after mild monocyte enrichment by cold aggregation.

579 After 5 hours the supernatant is removed and hourly photographic imaging is started. Video is a

580 composite of sequential images (time-lapse) for the first 48 hours. Note that the aggregates start as a

581 loose collection of cells and become larger and more compact by cell recruitment.

582 **References**

- 583 **Astrom K, Cohen JE, Willett-Brozick JE, Aston CE, Baysal BE. 2003.** Altitude is a  
584 phenotypic modifier in hereditary paraganglioma type 1: evidence for an oxygen-sensing defect.  
585 *Human Genetics* **113**: 228.
- 586 **Balik A, Penn AC, Nemoda Z, Greger IH. 2013.** Activity-regulated RNA editing in select  
587 neuronal subfields in hippocampus. *Nucleic Acids Research* **41**: 1124.
- 588 **Bayley JP, Devilee P, Taschner PE. 2005.** The SDH mutation database: an online resource for  
589 succinate dehydrogenase sequence variants involved in pheochromocytoma, paraganglioma and  
590 mitochondrial complex II deficiency. *BMC Medical Genetics* **6**: 39.
- 591 **Baysal BE. 2007.** A recurrent stop-codon mutation in succinate dehydrogenase subunit B gene in  
592 normal peripheral blood and childhood T-cell acute leukemia. *PloS One* **2**: e436.
- 593 **Baysal BE, Ferrell RE, Willett-Brozick JE, Lawrence EC, Myssiorek D, Bosch A, van der**  
594 **Mey A, Taschner PE, Rubinstein WS, Myers EN, Richard CW,3rd, Cornelisse CJ, Devilee**  
595 **P, Devlin B. 2000.** Mutations in SDHD, a mitochondrial complex II gene, in hereditary  
596 paraganglioma. *Science (New York, N.Y.)* **287**: 848.
- 597 **Baysal BE, McKay SE, Kim YJ, Zhang Z, Alila L, Willett-Brozick JE, Pacak K, Kim TH,**  
598 **Shadel GS. 2011.** Genomic imprinting at a boundary element flanking the SDHD locus. *Human*  
599 *Molecular Genetics* **20**: 4452.
- 600 **Berger AH, Knudson AG, Pandolfi PP. 2011.** A continuum model for tumour suppression.  
601 *Nature* **476**: 163.
- 602 **Blanc V, Davidson NO. 2003.** C-to-U RNA editing: mechanisms leading to genetic diversity.  
603 *The Journal of Biological Chemistry* **278**: 1395.

604 **Brazma A, Parkinson H, Sarkans U, Shojatalab M, Vilo J, Abeygunawardena N, Holloway**  
605 **E, Kapushesky M, Kemmeren P, Lara GG, Oezcimen A, Rocca-Serra P, Sansone SA. 2003.**  
606 **ArrayExpress--a public repository for microarray gene expression data at the EBI. *Nucleic Acids***  
607 ***Research* 31: 68.**

608 **Burnichon N, Abermil N, Buffet A, Favier J, Gimenez-Roqueplo AP. 2012.** The genetics of  
609 paragangliomas. *European Annals of Otorhinolaryngology, Head and Neck Diseases* 129: 315.

610 **Cerecer-Gil NY, Figuera LE, Llamas FJ, Lara M, Escamilla JG, Ramos R, Estrada G,**  
611 **Hussain AK, Gaal J, Korpershoek E, de Krijger RR, Dinjens WN, Devilee P, Bayley JP.**  
612 **2010.** Mutation of SDHB is a cause of hypoxia-related high-altitude paraganglioma. *Clinical*  
613 *Cancer Research : an official journal of the American Association for Cancer Research* 16:  
614 4148.

615 **Chang YF, Imam JS, Wilkinson MF. 2007.** The nonsense-mediated decay RNA surveillance  
616 pathway. *Annual Review of Biochemistry* 76: 51.

617 **Dahia PL, Ross KN, Wright ME, Hayashida CY, Santagata S, Barontini M, Kung AL,**  
618 **Sanso G, Powers JF, Tischler AS, Hodin R, Heitritter S, Moore F, Dluhy R, Sosa JA, Ocal**  
619 **IT, Benn DE, Marsh DJ, Robinson BG, Schneider K, Garber J, Arum SM, Korbonits M,**  
620 **Grossman A, Pigny P, Toledo SP, Nose V, Li C, Stiles CD. 2005.** A HIF1alpha regulatory loop  
621 links hypoxia and mitochondrial signals in pheochromocytomas. *PLoS Genetics* 1: 72.

622 **Derrien T, Johnson R, Bussotti G, Tanzer A, Djebali S, Tilgner H, Guernec G, Martin D,**  
623 **Merkel A, Knowles DG, Lagarde J, Veeravalli L, Ruan X, Ruan Y, Lassmann T, Carninci P,**  
624 **Brown JB, Lipovich L, Gonzalez JM, Thomas M, Davis CA, Shiekhhattar R, Gingeras TR,**  
625 **Hubbard TJ, Notredame C, Harrow J, Guigo R. 2012.** The GENCODE v7 catalog of human

- 626 long noncoding RNAs: analysis of their gene structure, evolution, and expression. *Genome*  
627 *Research* **22**: 1775.
- 628 **Du P, Kibbe WA, Lin SM. 2008.** lumi: a pipeline for processing Illumina microarray.  
629 *Bioinformatics (Oxford, England)* **24**: 1547.
- 630 **Garrett S, Rosenthal JJ. 2012.** RNA editing underlies temperature adaptation in K<sup>+</sup> channels  
631 from polar octopuses. *Science (New York, N.Y.)* **335**: 848.
- 632 **Guzy RD, Sharma B, Bell E, Chandel NS, Schumacker PT. 2008.** Loss of the SdhB, but Not  
633 the SdhA, subunit of complex II triggers reactive oxygen species-dependent hypoxia-inducible  
634 factor activation and tumorigenesis. *Molecular and Cellular Biology* **28**: 718.
- 635 **Huang da W, Sherman BT, Lempicki RA. 2009.** Systematic and integrative analysis of large  
636 gene lists using DAVID bioinformatics resources. *Nature Protocols* **4**: 44.
- 637 **Kaelin WG, Jr, Ratcliffe PJ. 2008.** Oxygen sensing by metazoans: the central role of the HIF  
638 hydroxylase pathway. *Molecular Cell* **30**: 393.
- 639 **Kita K, Hirawake H, Miyadera H, Amino H, Takeo S. 2002.** Role of complex II in anaerobic  
640 respiration of the parasite mitochondria from *Ascaris suum* and *Plasmodium falciparum*.  
641 *Biochimica et Biophysica Acta* **1553**: 123.
- 642 **Kleinman CL, Adoue V, Majewski J. 2012.** RNA editing of protein sequences: a rare event in  
643 human transcriptomes. *RNA (New York, N.Y.)* **18**: 1586.
- 644 **Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, Marth G, Abecasis G, Durbin**  
645 **R, 1000 Genome Project Data Processing Subgroup. 2009.** The Sequence Alignment/Map  
646 format and SAMtools. *Bioinformatics (Oxford, England)* **25**: 2078.
- 647 **Livak KJ, Schmittgen TD. 2001.** Analysis of relative gene expression data using real-time  
648 quantitative PCR and the 2<sup>-</sup>(-Delta Delta C(T)) Method. *Methods (San Diego, Calif.)* **25**: 402.

- 649 **Mentzer SJ, Guyre PM, Burakoff SJ, Faller DV. 1986.** Spontaneous aggregation as a  
650 mechanism for human monocyte purification. *Cellular Immunology* **101**: 312.
- 651 **Muller M, Mentel M, van Hellemond JJ, Henze K, Woehle C, Gould SB, Yu RY, van der**  
652 **Giezen M, Tielens AG, Martin WF. 2012.** Biochemistry and evolution of anaerobic energy  
653 metabolism in eukaryotes. *Microbiology and Molecular biology Reviews : MMBR* **76**: 444.
- 654 **Nishikura K. 2010.** Functions and regulation of RNA editing by ADAR deaminases. *Annual*  
655 *Review of Biochemistry* **79**: 321.
- 656 **Park E, Williams B, Wold BJ, Mortazavi A. 2012.** RNA editing in the human ENCODE  
657 RNA-seq data. *Genome Research* **22**: 1626.
- 658 **Piskol R, Peng Z, Wang J, Li JB. 2013.** Lack of evidence for existence of noncanonical RNA  
659 editing. *Nature Biotechnology* **31**: 19.
- 660 **Porcheray F, Viaud S, Rimaniol AC, Leone C, Samah B, Dereuddre-Bosquet N, Dormont**  
661 **D, Gras G. 2005.** Macrophage activation switching: an asset for the resolution of inflammation.  
662 *Clinical and Experimental Immunology* **142**: 481.
- 663 **Roiniotis J, Dinh H, Masendycz P, Turner A, Elsegood CL, Scholz GM, Hamilton JA. 2009.**  
664 Hypoxia prolongs monocyte/macrophage survival and enhanced glycolysis is associated with  
665 their maturation under aerobic conditions. *Journal of Immunology (Baltimore, Md.: 1950)* **182**:  
666 7974.
- 667 **Rutter J, Winge DR, Schiffman JD. 2010.** Succinate dehydrogenase - Assembly, regulation and  
668 role in human disease. *Mitochondrion* **10**: 393.
- 669 **Saldana MJ, Salem LE, Travezan R. 1973.** High altitude hypoxia and chemodectomas. *Human*  
670 *Pathology* **4**: 251.

- 671 **Sanjana NE, Levanon EY, Hueske EA, Ambrose JM, Li JB. 2012.** Activity-dependent A-to-I  
672 RNA editing in rat cortical neurons. *Genetics* **192**: 281.
- 673 **Schneider CA, Rasband WS, Eliceiri KW. 2012.** NIH Image to ImageJ: 25 years of image  
674 analysis. *Nature Methods* **9**: 671.
- 675 **Selak MA, Armour SM, MacKenzie ED, Boulahbel H, Watson DG, Mansfield KD, Pan Y,**  
676 **Simon MC, Thompson CB, Gottlieb E. 2005.** Succinate links TCA cycle dysfunction to  
677 oncogenesis by inhibiting HIF-alpha prolyl hydroxylase. *Cancer Cell* **7**: 77.
- 678 **Skuse GR, Cappione AJ, Sowden M, Metheny LJ, Smith HC. 1996.** The neurofibromatosis  
679 type I messenger RNA undergoes base-modification RNA editing. *Nucleic Acids Research* **24**:  
680 478.
- 681 **Smyth GK. 2004.** Linear models and empirical bayes methods for assessing differential  
682 expression in microarray experiments. *Statistical Applications in Genetics and Molecular*  
683 *Biology* **3**: Article3.
- 684 **Tilgner H, Knowles DG, Johnson R, Davis CA, Chakraborty S, Djebali S, Curado J,**  
685 **Snyder M, Gingeras TR, Guigo R. 2012.** Deep sequencing of subcellular RNA fractions shows  
686 splicing to be predominantly co-transcriptional in the human genome but inefficient for  
687 lncRNAs. *Genome Research* **22**: 1616.
- 688 **Uitenbroek DG** *SISA Binomial*. 2013.  
689 <http://www.quantitativeskills.com/sisa/distributions/binomial.htm>. Last accessed 4/4/2013.

**Table 1**(on next page)

Percentage of C136U transcripts estimated by allele specific (AS) qPCR and high-throughput amplicon sequencing in normoxic cultures

**Table 1**

**Percentage of C136U transcripts estimated by allele specific (AS) qPCR and high-throughput amplicon sequencing in normoxic cultures**

| Sample No. | Day in culture | AS qPCR | high-throughput sequencing <sup>a</sup> |
|------------|----------------|---------|---|
| 1          | Day 3          | 2.2%    | NR <sup>b</sup>                         |
| 1          | Day 6          | 15.9%   | 22%                                     |
| 2          | Day 3          | 1.3%    | NR                                      |
| 2          | Day 8          | 12.3%   | 23%                                     |
| 3          | Day 3          | 4%      | NR                                      |
| 3          | Day 6          | 13.5%   | 15%                                     |
| 4          | Day 3          | 8.7%    | 11%                                     |
| 4          | Day 7          | 18.8%   | 26%                                     |


<sup>a</sup> Sequencing depth ranges between 4980 and 4986 for the reported variants.

<sup>b</sup> NR= Not reported. Variants detected by high-throughput sequencing are reported only when their frequency exceeds 10%.

## Figure 1

SDHB C136U RNA editing is induced in monocytes during short-term culture.

**(A)** C136U editing is measured in 9 lymphoblastoid cell lines and one fibroblastic cell line, freshly isolated PBMCs (n=50), PBMCs monocyte-enriched by cold-aggregation (Mono+; n=42) and monocyte-depleted PBMCs comprised of largely lymphocytes (Mono-; n=10). Horizontal lines represent mean  $\pm$  standard errors throughout the figures. **(B)** Fraction of the C136U transcripts weakly correlates with the CD14+ monocyte percentage in monocyte-enriched PBMCs (Pearson correlation coefficient  $r=0.36$ ). **(C)** Impact of short-term culture on C136U editing. Short-term culture of five monocyte-enriched PBMCs shows upregulation of C136U editing in adherent cells in culture days 5-7 compared to days 1-3. Day 0 represents the uncultured samples. **(D)** Flow cytometric sorting of CD14+ versus CD14- adherent cells on culture days 5-8 shows higher mutation rates in monocyte-macrophage lineage than in lymphocytes ( $P=0.04$ ,  $n=5$ , Wilcoxon matched pairs signed ranks test). **(E)** C136U editing is lower among non-adherent cells in the supernatant than in adherent cells (4.3% versus 9.8%) on culture days 5-7 ( $n=19$  wells from 11 samples on days 5-7,  $P=2.1 \times 10^{-4}$ , Wilcoxon matched pairs signed ranks test).




## Figure 2

*SDHB* C136U RNA editing rate correlates with adherent monocyte-rich adherent aggregates (AA) in normoxic culture.

The AAs on culture days 1 (**A**) and 5 (**B**) are shown (5X low power field; vertical bars equal to 1 mm). The culture is initiated with 30 million cells per well. The AAs grow in size until approximately days 5-7 when the C136U editing rate also usually peaks. (**C**) High editing rates are seen in cultures with intermediate and high density of adherent aggregates. Aggregate densities are grouped as follows: Low= less than 10 aggregates/per 5X low power field (lpf); Intermediate=10-20 aggregates/lpf; High= more than 20 aggregates/lpf (**D**) Giemsa stain highlights an adherent aggregate on day 6 culture. Individually attached mature macrophages have mostly round eccentric nuclei and abundant cytoplasm. Occasional multi-nucleated macrophages (arrowheads) and rare small lymphocytes (green arrows) are also present. Macrophages within the aggregate are smaller with less cytoplasm and occasionally have curved nuclei (arrows). (**E**) CD163 immunostaining of adherent aggregates. Immunocytochemical staining for monocyte-macrophage-specific antigen CD163, a scavenger receptor for hemoglobin-haptoglobin complex, demonstrates that the adherent aggregates are primarily comprised of monocyte/macrophage lineage cells. Individually attached macrophages outside the aggregate also stain with variable intensity (short arrows); while numerous small lymphocytes are negative (long arrows).


Figure 2



## Figure 3

SDHB C136U RNA editing increases during monocyte-macrophage maturation.

Flow cytometric evaluation of monocyte-macrophage maturation is shown in uncultured cold aggregated PBMCs (first column), adherent cells on culture day 6 (second column) and adherent cells on culture day 15 (third column). The day 15 culture shows a relatively homogenous large (indicated by high forward scatter, FSC-A) macrophage population that has high complexity (indicated by high side scatter, SSC-A) and is positive for CD206 (mannose receptor), HLA-DR and CD163. In contrast, uncultured monocytes are largely a uniform population that is smaller with less complexity and is negative for CD206. The day 6 culture, which has 11.6% C136U editing rate, shows a CD14<sup>+</sup> population that is brightly positive for HLA-DR, dim-positive for CD206 and negative for CD163. CD14<sup>+</sup> monocyte-macrophage and lymphocyte populations are marked by green and red, respectively.



## Figure 4

Hypoxia induces *SDHB* C136U RNA editing.

**(A)** The editing rates are higher on days 1-3 in hypoxia and on days 5, 6 in normoxia. The average of four independent cultures is presented. **(B)** C136U editing rates in 12 independent cultures in hypoxia versus normoxia during 3 days of culture are shown. The editing rates were obtained from supernatant in all hypoxic cultures (first column) and from total cell population in normoxic cultures, except in two normoxic cultures where only supernatant was collected (second column). D0 samples represent the original uncultured cold aggregated PBMCs. **(C)** PCR amplification and *Taq1* restriction enzyme (RE) digestion shows no evidence of C136T DNA mutation in *SDHB* exon 2 genomic DNA (gDNA) (right panel) in the same samples with high C136U RNA editing rates (left panel). The C13U RNA editing rates above the lanes were measured by AS qPCR. RT- and gDNA-PCRs generate amplicon sizes of 285 bp and 233 bp, respectively. *Taq1* RE digestion of wild type cDNA and gDNA sequences generates 159 bp/126 bp and 131 bp/102 bp bands, respectively. C136U/T mutation destroys the RE site. **(D)** Western blot analysis of normoxic (N) and hypoxic (H) cultures from one donor shows no major changes in *SDHB* protein expression, normalized against beta actin, as the editing rate increases in hypoxia, but possibly a subtle decrease when the C136U percentage is 16.1% on day 2 in hypoxia. Hypoxic cultures were sampled twice a day, 10 h apart. **(E)** The editing rates are shown for flow sorted CD14<sup>+</sup> and CD14<sup>-</sup> viable cells from day 2 hypoxic cultures (n=4). In all experiments, hypoxic and control normoxic culture derive from the same donor (i.e., oxygen tension is the only variable).

